Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2021 01:00 ET | Source: Novartis Pharma AG

Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées

Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de...
July 20, 2021 07:05 ET | Source: Novartis Pharma AG

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and...
June 28, 2021 01:00 ET | Source: Novartis Pharma AG

Novartis appoints Rob Kowalski as Chief People & Organization Officer

Basel, June 28, 2021 — Novartis announced today the appointment of Rob Kowalski, Pharm.D., Global Head Regulatory Affairs and US Head of Drug Development as Chief People & Organization Officer. He...
June 18, 2021 12:30 ET | Source: Novartis Pharma AG

New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO...
June 11, 2021 03:00 ET | Source: Novartis Pharma AG

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal...
June 06, 2021 06:06 ET | Source: Novartis Pharma AG

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease...
June 04, 2021 09:05 ET | Source: Novartis Pharma AG

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta...
June 04, 2021 09:00 ET | Source: Novartis Pharma AG

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma...
June 03, 2021 17:05 ET | Source: Novartis Pharma AG

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30,...
June 03, 2021 12:04 ET | Source: Novartis Pharma AG

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or...